通过对接和动态模拟,对hVEGFR1的全面结构和功能分析:洞察酸化,分子相互作用和潜在的抑制剂
Manne Munikumar1, Jangampalli Adi Pradeepkiran2, Marineni Kiran Kumar3
1Clinical Division, ICMR-National Institute of Nutrition, Jamai-Osmania (Post), Hyderabad, 500007, Telangana, India.
Cancer treatment and research communications
|March 1, 2024
概括
研究人员探索了血管内皮生长因子受体1 (VEGFR1) 的人类氨酸激酶 (hTK) 域,以开发新的癌症药物. 这项研究揭示了针对血管新生相关疾病的向治疗的关键结构和相互作用见解.
科学领域:
- 生物化学和分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现 药物发现
背景情况:
- 血管内皮生长因子受体1 (VEGFR1) 对血管生成至关重要,并与非小细胞肺癌 (NSCLC) 等癌症有关.
- 现有的针对VEGFR1的药物面临药物耐药性和突变的挑战.
- 人类氨酸激酶 (hTK) 域的VEGFR1是一个有前途的治疗点肺癌.
研究的目的:
- 从结构和功能上表征VEGFR1.1的人类氨酸激酶 (hTK) 域.
- 确定针对hVEGFR1的潜在治疗策略,用于癌症和血管生成相关疾病.
- 为了阐明化合物与hVEGFR1 TK域之间的分子相互作用.
主要方法:
- 获取并分析了hVEGFR1 TK域的3D晶体结构 (PDB ID: 3HNG).
- 进行了分子相互作用分析,包括结合力阐明 (键,静电,疏水,π-sigma).
- 进行了分子动力学模拟,并分析了结构波动和全效应的对接复合体.
主要成果:
- 在hVEGFR1 TK域内确定了与酸化酶激酶和转移酶活动相关的独特区域.
- 发现了许多潜在的酸化部位,为蛋白质调节提供了洞察力.
- 详细介绍了分子与hVEGFR1的结合相互作用,证实了稳定性并揭示了动态形状变化.
结论:
- 这项研究提供了对hVEGFR1 TK域的全面描述.
- 这些发现支持开发针对hVEGFR1失调的新型向疗法.
- 这项研究有助于应对癌症和血管生成相关疾病的策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K


